IL SR0792

Urges the Department of Insurance, in consultation with insurance companies, medical practitioners, and other state departments, to conduct a study on phototherapy treatment costs and systemic inefficiencies for psoriasis patients in Illinois.

Requires examination of phototherapy copayment impacts on patient access, including number of patients receiving treatment, cost breakdowns (patient, provider, and insurance reimbursement rates), treatment termination rates, and reasons for discontinuation.

Directs study to analyze costs and impacts for patients using phototherapy for psoriasis and other diseases, and to track what alternative treatments patients use after stopping phototherapy.

Addresses concerns that high copayments (up to $50 per visit, potentially $600 monthly) deter psoriasis patients from using phototherapy despite it being safe and economical, causing them to pursue more expensive and riskier alternative treatments instead.

Notes that approximately 325,000 people in Illinois have psoriasis, with about 58,500 using phototherapy, and that 90% of healthcare providers surveyed agree that high copayments limit patient access to this treatment option.